9to5Mac

visionOS 2 tidbits: keyboard occlusion, Home View upgrades, more

Apple unveiled visionOS 2 at WWDC today, the first major update for Apple Vision Pro since last year. In addition to the features Apple highlighted on stage, there are a few other visionOS 2 tidbits ...
Healthline

Overview of Retinal Artery Occlusion

A retinal artery occlusion is a blockage in one of the blood vessels that supplies your retina with blood. It usually occurs suddenly and can cause vision loss without causing pain. A retinal artery ...
News Medical

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...
Business Wire

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials – Vabysmo showed robust and ...
Pharm Exec

Roche’s Vabysmo Shows Sustained Improvements in Vision, Retinal Drying in Retinal Vein Occlusion

Vabysmo is the first bispecific antibody approved to treat ocular conditions such as diabetic macular edema and wet age-related macular degeneration. “This is the first time that vision and anatomical ...
Nasdaq

New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)

Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema ...
Nasdaq

New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

Basel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due ...